Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Alnylam Pharmaceuticals, Inc.”

376 pharma patents match "Alnylam Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 376
Index total 30,257
Page 9 / 16

Quick answer

This filtered view shows 376 pharmaceutical patents matching "Alnylam Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

376 results for “Alnylam Pharmaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 9574192

    Serapina1 iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Feb 21, 2017 · Expires Feb 16, 2037

    granted
  2. US 9566295

    GNAQ targeted dsRNA compositions and methods for inhibiting expression

    Alnylam Pharmaceuticals, Inc. · Granted Feb 14, 2017 · Expires Feb 9, 2037

    granted
  3. US 9566340

    Monomers and oligonucleotides comprising cycloaddition adduct(s)

    Alnylam Pharmaceuticals, Inc. · Granted Feb 14, 2017 · Expires Feb 9, 2037

    granted
  4. US 9506067

    Compositions and methods for inhibiting expression of the HAMP gene

    Alnylam Pharmaceuticals, Inc. · Granted Nov 29, 2016 · Expires Nov 24, 2036

    granted
  5. US 9463247

    Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents

    Alnylam Pharmaceuticals, Inc. · Granted Oct 11, 2016 · Expires Oct 6, 2036

    granted
  6. US 9453222

    Ligand-conjugated monomers

    Alnylam Pharmaceuticals, Inc. · Granted Sep 27, 2016 · Expires Sep 22, 2036

    granted
  7. US 9441225

    Compositions and methods for inhibiting expression of factor V

    Alnylam Pharmaceuticals, Inc. · Granted Sep 13, 2016 · Expires Sep 8, 2036

    granted
  8. US 9422562

    Compositions and methods for inhibiting expression of CD274/PD-L1 gene

    Alnylam Pharmaceuticals, Inc. · Granted Aug 23, 2016 · Expires Aug 18, 2036

    granted
  9. US 9415109

    Stable non-aggregating nucleic acid lipid particle formulations

    Alnylam Pharmaceuticals, Inc. · Granted Aug 16, 2016 · Expires Aug 11, 2036

    granted
  10. US 9399775

    RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases

    Alnylam Pharmaceuticals, Inc. · Granted Jul 26, 2016 · Expires Jul 21, 2036

    granted
  11. US 9394540

    Modified iRNA agents

    Alnylam Pharmaceuticals, Inc. · Granted Jul 19, 2016 · Expires Jul 14, 2036

    granted
  12. US 9376680

    Serpinc1 iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Jun 28, 2016 · Expires Jun 23, 2036

    granted
  13. US 9370582

    Carbohydrate conjugates as delivery agents for oligonucleotides

    Alnylam Pharmaceuticals, Inc. · Granted Jun 21, 2016 · Expires Jun 16, 2036

    granted
  14. US 9370581

    Carbohydrate conjugates as delivery agents for oligonucleotides

    Alnylam Pharmaceuticals, Inc. · Granted Jun 21, 2016 · Expires Jun 16, 2036

    granted
  15. US 9352048

    Carbohydrate conjugates as delivery agents for oligonucleotides

    Alnylam Pharmaceuticals, Inc. · Granted May 31, 2016 · Expires May 26, 2036

    granted
  16. US 9339513

    Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes

    Alnylam Pharmaceuticals, Inc. · Granted May 17, 2016 · Expires May 12, 2036

    granted
  17. US 9322018

    Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Apr 26, 2016 · Expires Apr 21, 2036

    granted
  18. US 9315813

    Compositions and methods for inhibition of expression of apolipoprotein C-III (APOC3) genes

    Alnylam Pharmaceuticals, Inc. · Granted Apr 19, 2016 · Expires Apr 14, 2036

    granted
  19. US 9290760

    Modified iRNA agents

    Alnylam Pharmaceuticals, Inc. · Granted Mar 22, 2016 · Expires Mar 17, 2036

    granted
  20. US 9260718

    Compositions and methods for inhibiting expression of the PCSK9 gene

    Alnylam Pharmaceuticals, Inc. · Granted Feb 16, 2016 · Expires Feb 11, 2036

    granted
  21. US 9254327

    Methods and compositions for delivery of active agents

    Alnylam Pharmaceuticals, Inc. · Granted Feb 9, 2016 · Expires Feb 4, 2036

    granted
  22. US 9249415

    Complement component C5 iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Feb 2, 2016 · Expires Jan 28, 2036

    granted
  23. US 9234196

    Compositions and methods for inhibiting expression of transthyretin

    Alnylam Pharmaceuticals, Inc. · Granted Jan 12, 2016 · Expires Jan 7, 2036

    granted
  24. US 9228188

    Compositions and method for inhibiting hepcidin antimicrobial peptide (HAMP) or HAMP-related gene expression

    Alnylam Pharmaceuticals, Inc. · Granted Jan 5, 2016 · Expires Dec 31, 2035

    granted